Company Overview of Sanomune Inc.
Sanomune Inc. operates as a biopharmaceutical company that develops products for treatment of neurological and autoimmune disorders. The company’s products include SAN-61, which is used for the treatment of alzheimer's disease; SAN-121, which is nasally-delivered metal chelator that reduces cognitive decline in alzheimer's patients; and SAN-18, which is used for the treatment of rheumatoid arthritis. Its products are also used for treating multiple sclerosis and diabetes. The company was founded in 1999 and is based in Winnipeg, Canada. As of June 30, 2010, Sanomune Inc. operates as a subsidiary of Diamedica Inc.
7-1250 Waverley Street
Winnipeg, MB R3T 6C6
Founded in 1999
Key Executives for Sanomune Inc.
Sanomune Inc. does not have any Key Executives recorded.
Similar Private Companies By Industry
|1127466 B.C. Ltd.||Americas|
|9037136 Canada Inc.||Americas|
|AAA Heidelberg Inc.||Americas|
|Ab Biotech Inc.||Americas|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Sanomune Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.